



## Cara Therapeutics to Present at Upcoming Investor Conferences

November 2, 2022

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will present at the following investor conferences:

### Stifel Healthcare Conference

Tuesday, November 15, 2022, at 10:55 a.m. ET

### Jefferies London Healthcare Conference

Wednesday, November 16, 2022, at 10 a.m. ET (3 p.m. GMT)

### Evercore ISI Healthcare Conference (virtual)

Tuesday, November 29, 2022, at 8:25 a.m. ET

### Piper Sandler Healthcare Conference

Thursday, December 1, 2022, at 8 a.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com). Archived webcast recordings will be available on the Cara website for approximately 30 days.

### About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company's novel KORSUVA<sup>®</sup> (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com) and follow the company on [Twitter](#), [LinkedIn](#) and [Instagram](#).

### MEDIA CONTACT:

Annie Spinetta  
6 Degrees  
973-768-2170  
[aspinetta@6degreespr.com](mailto:aspinetta@6degreespr.com)

### INVESTOR CONTACT:

Iris Francesconi, Ph.D.  
Cara Therapeutics  
203-406-3700  
[investor@caratherapeutics.com](mailto:investor@caratherapeutics.com)



Source: Cara Therapeutics, Inc.